Pancreatic Cancer Research

ResearcherYanbian UniversityActive in the last 2 years

Liyan Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4730-9879; OpenAlex author ID A5114029839. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 5

  1. Elevated Expression of Tiam1 Is Associated with Poor Prognosis and Promotes Tumor Progression in Pancreatic Cancer [Retraction]. Last author DOI 10.2147/ott.s625411↗
  2. High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.gene.2019.02.081↗
  3. Elevated expression of Tiam1 is associated with poor prognosis and promotes tumor progression in pancreatic cancer. Last author DOI 10.2147/ott.s171425↗
  4. Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer. Last author PMID 30662800↗
  5. Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. Co-author DOI 10.3892/ol.2017.5821↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mina Ding · 1 shared paper, 2026 · strength 0.33
  2. Meiying Ji · 2 shared papers, 2017–2018 · strength 0.19
  3. Jie Lena Sun · 2 shared papers, 2017–2019 · strength 0.18
  4. Yang Yang · 2 shared papers, 2017–2018 · strength 0.17
  5. Zhenhua Lin · 2 shared papers, 2017–2018 · strength 0.17
  6. Zhenhua Lin · 1 shared paper, 2018 · strength 0.12
  7. Junjie Piao · 1 shared paper, 2019 · strength 0.11
  8. Mina Ding · 1 shared paper, 2018 · strength 0.09
  9. Aihua Jin · 1 shared paper, 2017 · strength 0.08
  10. Xuelian Cui · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.